• Bart Wuurman
    Bart Wuurman, Chief Executive Officer
    As multiple entrepreneur and pharmaceutical scientist, Bart Wuurman has been instrumental to the successful exits of biotech companies Lanthio Pharma and AM-Pharma in The Netherlands and Antisoma in the United Kingdom. He was involved with raising approximately € 80 million in equity funding. Before becoming CEO, Bart was VP Business Development and Licensing for Antisoma plc and Medeva plc in the United Kingdom, where he was responsible for out-licensing deals worth over €700 million. 
  • David Sherr
    Prof. Dr. David Sherr, Chief Scientific Officer 
    Prof Dr David Sherr is a founder of Hercules and has published over 100 peer-reviewed articles, many of which relate to AhR in cancer. David is Director of the Immunology Training Program at Boston University School Of Medicine and Director of the Boston University Superfund Research Program.
  • Dr Sjoerd Wadman, Development Director

    Dr Sjoerd Wadman, Development Director

    Sjoerd is a Medicinal Chemist with a strong track record in drug development. Previously he was VP R&D at Lanthio Pharma, Head of R&D at Novacta (UK) and Project leader at GSK (UK)

  • Dr Marie Cumberbatch, Immuno Oncology

    Dr Marie Cumberbatch, Immuno-Oncology 

    As immunologist, being part of the Immuno-Oncology team at Astra Zeneca, Marie was involved in the development of many small molecule IO drugs.